Holen Sie sich die Stockscreener-App
1.27
4.51%
-0.06
Handel nachbörslich:
1.27
Schlusskurs vom Vortag:
$1.33
Offen:
$1.3
24-Stunden-Volumen:
365.53K
Relative Volume:
2.07
Marktkapitalisierung:
$44.11M
Einnahmen:
$2.91M
Nettoeinkommen (Verlust:
$-220.40M
KGV:
-0.3489
EPS:
-3.64
Netto-Cashflow:
$-176.15M
1W Leistung:
+1.60%
1M Leistung:
-3.05%
6M Leistung:
-87.35%
1J Leistung:
-85.42%
1-Tages-Spanne:
$1.2301
$1.3786
1-Wochen-Bereich:
$1.20
$1.42
52-Wochen-Spanne:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Firmenname
Igm Biosciences Inc
Sektor
Branche
Telefon
650-965-7873
Adresse
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Vergleichen Sie IGMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.27 | 75.14M | 2.91M | -220.40M | -176.15M | -3.64 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-01-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-10-01 | Herabstufung | Truist | Buy → Hold |
| 2024-02-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | Fortgesetzt | Jefferies | Buy |
| 2022-10-17 | Eingeleitet | JP Morgan | Neutral |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2021-12-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-01-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-07-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-28 | Eingeleitet | SunTrust | Buy |
| 2020-04-22 | Eingeleitet | Wedbush | Outperform |
| 2019-10-14 | Eingeleitet | Guggenheim | Buy |
| 2019-10-14 | Eingeleitet | Jefferies | Buy |
| 2019-10-14 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-10-14 | Eingeleitet | Stifel | Buy |
Alle ansehen
Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World
IGM Biosciences Terminates Headquarters Lease Agreement - TipRanks
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
IGM Biosciences earnings missed by $0.51, revenue fell short of estimates - Investing.com Canada
Sanofi Invests $8.79 Million in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com Nigeria
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com
30,148 Shares in IGM Biosciences, Inc. (NASDAQ:IGMS) Bought by Cubist Systematic Strategies LLC - Defense World
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
IGM Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates - MSN
IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday - Defense World
IGM Biosciences (IGMS) to Release Earnings on Wednesday - MarketBeat
IGM Biosciences says it is dropping development of imvotamab - The Pharma Letter
IGM Biosciences ends agreement with Sanofi - Investing.com Australia
IGM Biosciences ends agreement with Sanofi By Investing.com - Investing.com South Africa
IGM Biosciences Ends Genzyme Collaboration, Cuts Workforce - TipRanks
Price T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Renaissance Technologies LLC Raises Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5%Here's Why - MarketBeat
IGM Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Bought by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Igm biosciences principal accounting officer sells $1,907 in stock - MSN
Q1 Biopharma Layoffs Hit California, Massachusetts Hard - BioSpace
5 Causes Behind Pharma Layoffs in 2025 - PharmiWeb.com
IGMS stock touches 52-week low at $1 amid sharp annual decline - Investing.com
IGMS stock touches 52-week low at $1 amid sharp annual decline By Investing.com - Investing.com South Africa
IGM Bio stock slips as Bank of America downgrades (IGMS:NASDAQ) - Seeking Alpha
Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com Australia
IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World
Finanzdaten der Igm Biosciences Inc-Aktie (IGMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):